NEW YORK, April 7, 2014 /PRNewswire/ -- Geron Corporation (NasdaqGS: GERN), an emerging competitor, is developing a telomerase inhibitor called Imetelstat in hematologic myeloid malignancies. Through internal efforts and potential future strategic partnerships, GERN is positioned to advance the commercialization of Imetelstat in one or more hematologic myeloid malignancies. The discovery and early development of Imetelstat was based on Geron's core expertise in telomerase and telomere biology. Telomerase is an enzyme that enables cancer cells, including malignant progenitor cells, to maintain telomere length, which provides them with the capacity for limitless proliferation.
There is a large available market with very few treatment alternatives that has been validated by the entry of such pharmaceutical giants as Sanofi (SNY) and Novartis (N). Geron's novel approach has no clear direct competition and has the potential to revolutionize the market.
The Company is facing a near term regulatory hurdle that has temporarily set back clinical trials and development efforts which management is in the process of addressing with the highest priority.
The Company has recently filed its FY2013 Form 10K annual financial report and related disclosures which provide an update on operating considerations and the latest financial information for investors.
An analyst report which details key attributes of the technology, an overview of the company and analyst recommendation can be viewed in its entirety by using the link below. There is no cost required to view this report:
copy and paste to browser may be required.
This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward- looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is written and authored by Michael Andereg, CFA. An outsourced research services provider represented by Michael Andereg, CFA, provided Small Cap Street, LLC this article or report. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. Small Cap Street, LLC and BrokerBank Securities, Inc. are not entitled to veto, interfere or alter the articles, documents or report once created and reviewed by the outsourced research provider represented by Michael Andereg, CFA.
If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at firstname.lastname@example.org. For any urgent concerns or inquiries, please contact us at email@example.com.
NO WARRANTY OR LIABILITY ASSUMED
GERN has not compensated Small Cap Street, LLC, BrokerBank Securities, Inc., or Michael Andereg, CFA for the creation or dissemination of this report. Small Cap Street, LLC and BrokerBank Securities, Inc., is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. Small Cap Street, LLC and BrokerBank Securities, Inc. do not hold any positions in GERN. No liability is accepted by Small Cap Street, LLC and BrokerBank Securities, Inc. whatsoever for any direct, indirect or consequential loss arising from the use of this document. Small Cap Street, LLC and BrokerBank Securities, Inc. expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Small Cap Street, LLC and BrokerBank Securities, Inc. do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
Small Cap Street, LLC is the party responsible for hosting the full analyst report. BrokerBank Securities in the party responsible for issuing the press release and Michael Andereg, CFA, is the author of research report. Small Cap Street, LLC has compensated Michael Andereg, CFA two hundred dollars and fifty dollars for the right to disseminate this report. BrokerBank Securities has been compensated one hundred dollars to issue press release by Small Cap Street, LLC. Information in this release is fact checked and produced on a best efforts basis by Michael Andereg, CFA.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
BrokerBank Securities, Inc. is a member of the Financial Industry Regulatory Authority, CRD number #130116.
SOURCE BrokerBank Securities, Inc.